These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 26438742)

  • 1. Broad Hepatitis C Treatment Scenarios Return Substantial Health Gains, But Capacity Is A Concern.
    Van Nuys K; Brookmeyer R; Chou JW; Dreyfus D; Dieterich D; Goldman DP
    Health Aff (Millwood); 2015 Oct; 34(10):1666-74. PubMed ID: 26438742
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic burden of hepatitis C in Egypt: the future impact of highly effective therapies.
    Estes C; Abdel-Kareem M; Abdel-Razek W; Abdel-Sameea E; Abuzeid M; Gomaa A; Osman W; Razavi H; Zaghla H; Waked I
    Aliment Pharmacol Ther; 2015 Sep; 42(6):696-706. PubMed ID: 26202593
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estimating the cost-effectiveness of needle-syringe programs in Australia.
    Kwon JA; Anderson J; Kerr CC; Thein HH; Zhang L; Iversen J; Dore GJ; Kaldor JM; Law MG; Maher L; Wilson DP
    AIDS; 2012 Nov; 26(17):2201-10. PubMed ID: 22914579
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Short-term budget affordability of hepatitis C treatments for state Medicaid programs.
    Chou JW; Silverstein AR; Goldman DP
    BMC Health Serv Res; 2019 Feb; 19(1):140. PubMed ID: 30819153
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Cost-effective medical therapy of hepatitis C employing novel compensation models - pay for cure].
    Foerster F; Wörns MA; Galle PR; Schattenberg JM
    Z Gastroenterol; 2015 Dec; 53(12):1414-21. PubMed ID: 26666278
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Costs and cost-effectiveness of different follow-up schedules for detection of occupational hepatitis C virus infection.
    Deuffic-Burban S; Abiteboul D; Lot F; Branger M; Bouvet E; Yazdanpanah Y
    Gut; 2009 Jan; 58(1):105-10. PubMed ID: 18824553
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Routine hepatitis C virus screening in pregnancy: a cost-effectiveness analysis.
    Plunkett BA; Grobman WA
    Am J Obstet Gynecol; 2005 Apr; 192(4):1153-61. PubMed ID: 15846195
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The enigma of value: in search of affordable and accessible health care.
    Szucs TD; Weiss M; Klaus G
    Eur J Health Econ; 2017 Jul; 18(6):667-670. PubMed ID: 27913941
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The economic burden of diabetes.
    Dall TM; Zhang Y; Chen YJ; Quick WW; Yang WG; Fogli J
    Health Aff (Millwood); 2010 Feb; 29(2):297-303. PubMed ID: 20075080
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Guide to the Economics of Hepatitis C Virus Cure in 2017.
    Linas BP; Nolen S
    Infect Dis Clin North Am; 2018 Jun; 32(2):447-459. PubMed ID: 29778265
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of peginterferon alfa-2a (40kDa) plus ribavirin in patients with HIV and hepatitis C virus co-infection.
    Hornberger J; Torriani FJ; Dieterich DT; Bräu N; Sulkowski MS; Torres MR; Green J; Patel K
    J Clin Virol; 2006 Aug; 36(4):283-91. PubMed ID: 16765638
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Economic costs of diabetes in the U.S. In 2007.
    American Diabetes Association
    Diabetes Care; 2008 Mar; 31(3):596-615. PubMed ID: 18308683
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hospitalizations and costs associated with hepatitis C and advanced liver disease continue to increase.
    Xu F; Tong X; Leidner AJ
    Health Aff (Millwood); 2014 Oct; 33(10):1728-35. PubMed ID: 25288416
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A model of the economic benefits of global hepatitis C elimination: an investment case.
    Scott N; Kuschel C; Pedrana A; Schroeder S; Howell J; Thompson A; Wilson DP; Hellard M
    Lancet Gastroenterol Hepatol; 2020 Oct; 5(10):940-947. PubMed ID: 32730785
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Case finding for hepatitis C in primary care: a cost utility analysis.
    Thompson Coon J; Castelnuovo E; Pitt M; Cramp M; Siebert U; Stein K
    Fam Pract; 2006 Aug; 23(4):393-406. PubMed ID: 16799165
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Global epidemiology and burden of hepatitis C.
    Ray Kim W
    Microbes Infect; 2002 Oct; 4(12):1219-25. PubMed ID: 12467763
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Financial burden of hepatitis C infection and its treatment].
    Makara M; Hunyady B
    Orv Hetil; 2015 May; 156(21):862-8. PubMed ID: 26038994
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The economics of routine childhood hepatitis A immunization in the United States: the impact of herd immunity.
    Armstrong GL; Billah K; Rein DB; Hicks KA; Wirth KE; Bell BP
    Pediatrics; 2007 Jan; 119(1):e22-9. PubMed ID: 17200247
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aging diseases--do they prevent preventive health care from saving costs?
    Gandjour A
    Health Econ; 2009 Mar; 18(3):355-62. PubMed ID: 18833543
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Motor vehicle safety, health care, and taxes. National Highway Traffic Safety Administration, U.S. Department of Transportation.
    Prehosp Disaster Med; 1994; 9(1):11-23. PubMed ID: 10155483
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.